May 24, 2019 — Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor…Original Article
FDA Approves Piqray (alpelisib) as First PI3K Inhibitor for Breast Cancer
